Nuvectis Pharma, Inc. (NVCT)

NCM – Real Time Price. Currency in USD

10.90

-0.16 (-1.45%)

At close: May 12, 2026, 4:00 PM EDT

10.90

0.00 (0.00%)

After-hours: May 12, 2026, 4:10 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Nuvectis Pharma, Inc. (NVCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Nuvectis Pharma, Inc. (NVCT)

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Videos

No Data

Press releases

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Search stocks

Nuvectis Pharma, Inc. (NVCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Nuvectis Pharma, Inc. (NVCT)

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Videos

No Data

Press releases

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC